EndoChoice, a company focusing on manufacturing specialized endoscopic imaging, has announced its latest study results confirming the efficacy of the Fuse Full Spectrum Endoscopy System at the American College of Gastroenterology (ACG) Annual Scientific Session in Philadelphia, PA, and the United European Gastroenterology Week (UEGW) in Vienna, Austria.
Even though colonoscopy is the standard method used for screening, surveillance and diagnosis in lower gastrointestinal malignancies, recent studies have found that between 24% and 33% of adenomas are missed in the first colonoscopy.
Fuse Full Spectrum Endoscopy presents an innovative technology that allows for a 330° field of view, enabling clinicians to see almost twice as much anatomy as traditional endoscopes, including the areas behind colonic and pyloric folds.
Furthermore, the system is equipped with LEDs, which allow for a significantly improved visibility and added longevity and durability beyond fiber optic illumination.
Several researchers at different sites have acknowledged that the ability to see an increased 94% of anatomy with the Fuse system has a significant impact on the capacity to “detect precancerous lesions, efficiency in navigating the GI tract, and reductions in sedation requirements, when compared to traditional forward-viewing (TFV) endoscopes”, as stated in an EndoChoice’s news release.
Importantly, it has been estimated that the Fuse system can potentially prevent around 10,318 colorectal cancer diagnoses in the U.S. alone, further translating into annual savings of $300,000,000 for the U.S. healthcare system.
At UEGW, Dr. Helmut Neumann presented data from a randomized study that compared the efficiency between Fuse and TFV endoscopes. A total of 57 patients underwent colonoscopy with either one of these systems, and several variables such as medication, patient and endoscopists’ satisfaction, and polyp detection rates (PDR) were registered.
The results demonstrated that even though satisfaction rates were similar in both groups, patients in the TVF group received more sedation.
Furthermore, patients in the Fuse group had a higher (37%) rate of registered polyps, when compared to the 18% registered for the TFV group.
“The mission of EndoChoice is to serve the GI caregiver through insight and innovation,” Mark Gilreath, Founder and CEO at EndoChoice said in a press release. “The studies presented at UEGW and ACG this week provide further confirmation that Fuse enables physicians to provide a higher level of care for patients and further advance their practices.”
